CoChat

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis

Open access
Li, H, Zhang, Y, Ströse, A, Tedesco, D, Gurova, K, Selivanova, G · 2014 · Cell Death & Differentiation
Cited by 66

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The restoration of p53 tumor suppressor function is a promising therapeutic strategy to combat cancer. However, the biological outcomes of p53 activation, ranging from the promotion of growth arrest to the induction of cell death, are hard to predict, which limits the clinical application of p53-based therapies. In the present study, we performed an integrated analysis of genome-wide short hairpin RNA screen and gene expression data and uncovered a previously unrecognized role of Sp1 as a central modulator of the transcriptional response induced by p53 that leads to robust induction of apoptosis. Sp1 is indispensable for the pro-apoptotic transcriptional repression by p53, but not for the induction of pro-apoptotic genes. Furthermore, the p53-dependent pro-apoptotic transcriptional repression required the co-binding of Sp1 to p53 target genes. Our results also highlight that Sp1 shares with p53 a common regulator, MDM2, which targets Sp1 for proteasomal degradation. This uncovers a new mechanism of the tight control of apoptosis in cells. Our study advances the understanding of the molecular basis of p53-mediated apoptosis and implicates Sp1 as one of its key modulators. We found that small molecules reactivating p53 can differentially modulate Sp1, thus providing insights into how to manipulate p53 response in a controlled way.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cdd.2014.69

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 25

  1. Selivanova G . Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 2010; 20: 46–56. · DOI
  2. Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339–1345. · DOI · Paper page
  3. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441–453. · DOI
  4. Xiong L, Kou F, Yang Y, Wu J . A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol 2007; 178: 995–1007. · DOI
  5. Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem 2011; 286: 41600–41615. · DOI · Paper page
  6. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19: 1992–2002. · DOI · Paper page
  7. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70: 5807–5817. · DOI · Paper page
  8. Bocangel D, Sengupta S, Mitra S, Bhakat KK . p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009; 29: 3741–3750.
  9. Gualberto A, Baldwin AS Jr . p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 1995; 270: 19680–19683. · DOI · Paper page
  10. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431–437. · DOI · Paper page
  11. Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202–206. · DOI · Paper page
  12. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2: 474–479. · DOI · Paper page
  13. Hilton TL, Li Y, Dunphy EL, Wang EH . TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. Mol Cell Biol 2005; 25: 4321–4332. · DOI
  14. Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD . Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002; 21: 1485–1492. · DOI
  15. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G . MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171–183. · DOI · Paper page
  16. Pećina-Slaus N . Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int 2010; 10: 22. · DOI · Paper page
  17. Zeng L, Rowland RG, Lele SM, Kyprianou N . Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004; 35: 290–297. · doi:10.1016/j.humpath.2003.11.001
  18. Brown L, Benchimol S . The involvement of MAPK signaling pathways in determining the cellular response to p53 activation: cell cycle arrest or apoptosis. J Biol Chem 2006; 281: 3832–3840. · DOI
  19. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2012; 10: 1590–1598. · DOI · Paper page
  20. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs Nutlin-3 and RITA. Cancer Res 2009; 69: 6241–6248. · DOI
  21. Ferlini C, Scambia G . Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc 2007; 2: 3111–3114. · DOI
  22. Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011; 10: 3346–3358. · DOI · Paper page
  23. Huang DW, Sherman BT, Lempicki RA . Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44–57. · DOI · Paper page
  24. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19: Unit 19.10.1-21.
  25. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 2005; 33: 3154–3164. · DOI · Paper page

Cited by

Metadata

Authors
Li, H., Zhang, Y., Ströse, A., Tedesco, D., Gurova, K., & Selivanova, G.
Venue
Cell Death & Differentiation
Published
2014-06-27
Volume
21
Issue
9
Pages
1493-1502
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2091392106
Cited by
66
References
10
FWCI
3.45
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.